Craft

CHA Vaccine Institute

Revenue

₩294.1 M

FY, 2023

CHA Vaccine Institute Summary

Company Summary

Overview
CHA Vaccine Institute ((주)차백신연구소, formerly known as Dubeel) is a research-oriented biotechnology company. It researches and develops vaccine products targeting infectious diseases as well as chronic diseases. It creates 3rd gen. Hepatitis B vaccine (HBV), HBV therapeutic vaccine, zoster vaccine, flu vaccine, adjuvants, and recombinant mannan-binding lectins. The company also has a recombinant antigen development platform with this platform the company has developed an improved prophylactic vaccine for infectious diseases and a therapeutic vaccine for chronic disease.
Type
Public
Status
Active
Founded
2000
HQ
Seongnam, KR | view all locations
Website
http://en.chavaccine.com/
Sectors

Key People

  • Jung Sun Yum, Chief Executive Officer

    • Hong Mo Moon, Founder

      LocationsView all

      1 location detected

      • Seongnam, Gyeonggi-do HQ

        Korea (Republic of)

        560 Dunchon-daero, Jungwon-gu

      CHA Vaccine Institute Financials

      Summary Financials

      Gross profit (Q2, 2024)
      ₩8.7M
      Net income (Q2, 2024)
      (₩2.7B)
      Cash (Q2, 2024)
      ₩5.2B
      EBIT (Q2, 2024)
      (₩2.1B)

      Footer menu